Search Result

Results for "

CAVS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adrenergic Receptor (1) Angiotensin Receptor (1) Apoptosis (12) Calcium Channel (59) Drug Metabolite (1) Endogenous Metabolite (12) Fungal (3) Integrin (1) Isotope-Labeled Compounds (9) Monoamine Transporter (2) P2Y Receptor (1) Parasite (1) Potassium Channel (3) Reactive Oxygen Species (18) Small Interfering RNA (siRNA) (3) Sodium Channel (4)
By Research Areas:	Cancer (20) Cardiovascular Disease (18) Endocrinology (2) Infection (4) Inflammation/Immunology (5) Metabolic Disease (12) Neurological Disease (46)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Menaquinone-7 1 Publications Verification Vitamin K2-7; Vitamin K2(35); Vitamin MK-7	Others	Cardiovascular Disease
Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .

CaV1.3 antagonist-1	Calcium Channel	Neurological Disease
CaV1.3 antagonist-1 is a potent and highly selective Ca_V1.3 L-type calcium channel (LTCC) antagonist with an IC₅₀ of 1.7 μM. CaV1.3 antagonist-1 inhibits Ca_V1.3 LTCC >600-fold more potently than Ca_V1.2 LTCC. CaV1.3 antagonist-1, a cyclopentyl derivative, has the potential for Parkinson's disease research .

ML218 1 Publications Verification	Calcium Channel	Neurological Disease
ML218 is a potent, selective and orally active T-type Ca ²⁺ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for *Cav3.2* and *Cav3.3*, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, K_ATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

Cav 2.2 blocker 2	Calcium Channel	Neurological Disease
Cav 2.2 blocker 2 is a Cav2.2 calcium channel blocker extracted from patent WO2017046581A1, compound 1. Cav 2.2 blocker 2 can reverses hyperalgesia associated with an injury or inflammation in conjunction with the opioid .

N-Desalkylflurazepam Norfludiazepam	Calcium Channel	Neurological Disease
N-Desalkylflurazepam (Norfludiazepam) is a long-acting metabolite of benzodiazepine compounds, such as Flurazepam. N-Desalkylflurazepam inhibits L-type voltage-gated calcium channels with IC₅₀ values of 55 μM and 37 μM for *Ca_v1.2* and *Ca_v1.3*, respectively .

ML218 hydrochloride	Calcium Channel	Neurological Disease
ML218 hydrochloride is a potent, selective and orally active T-type Ca ²⁺ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for *Cav3.2* and *Cav3.3*, respectively. ML218 hydrochloride inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 hydrochloride has no significant inhibition of L- or N-type calcium channels, K_ATP or hERG potassium channels. ML218 hydrochloride can penetrate the blood-brain barrier .

NSC156529	Calcium Channel	Neurological Disease Cancer
NSC156529 is a potent T-type calcium-channel antagonist. NSC156529 shows inhibits on Cav3.1 and Cav3.2 and o Cav3.3 without effect. NSC156529 has the potential for the research of neuropsychic and genital system diseases .

Cav 2.2/3.2 blocker 1	Calcium Channel	Neurological Disease
Cav 2.2/3.2 blocker 1 (Compound 9e) is a neuronal calcium channel blocker with IC₅₀ values of 78 μM and 80 μM against *Ca_v2.2* and *Ca_v3.2, respectively. Cav* 2.2/3.2 blocker 1 can penetrate the CNS .

ML218-d9	Calcium Channel	Neurological Disease
ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier[1].

Cav 3.2 inhibitor 4	Calcium Channel	Cardiovascular Disease
Cav 3.2 inhibitor 4 (compound 21) is a potent, peripherally restricted, selective T-type calcium channel (Ca_v3.2) inhibitor, with an IC₅₀ of 0.6 μM. Cav 3.2 inhibitor 4 can be used for the research of atrial fibrillation .

Cav 3.2 inhibitor 2	Calcium Channel	Neurological Disease
Cav 3.2 inhibitor 2 is a Ca_v3.2 T-type Ca ²⁺ channels inhibitor with an IC₅₀ of 0.09339 μM under -80mV holding potential. Cav 3.2 inhibitor 2 potently suppresses T-channel-dependent somatic and visceral pain in mice. Cav 3.2 inhibitor 2 can be used for the research of intractable pain .

CBD3063	Calcium Channel	Inflammation/Immunology
CBD3063 is a selective modulator of collapsin response mediator protein 2 (CRMP2). CBD3063 uncouples Cav2.2 from CRMP2. CBD3063 reverses neuropathic and inflammatory pain by reducing membrane expression of CaV2.2 .

Cav 3.2 inhibitor 3	Calcium Channel	Neurological Disease
Cav 3.2 inhibitor 3 (Compound 4) is a potent Ca_v3.2 T-type Ca ²⁺ channel inhibitor with an IC₅₀ of 0.1534 μM, and has little binding affinity to D₂ receptors .

BTT-266	Calcium Channel	Neurological Disease
BTT-266 is an antagonist forcalcium channel, through suppression of the Ca_Vα_1-AID-Ca_Vβ₃ interaction, with a K_i of 1.4 μM. BTT-266 modulates the activation of voltage-dependent Ca_V2.2. BTT-266 exhibits analgesic efficacy against neuropathic pain in rats model .

T-Type calcium channel inhibitor 2	Calcium Channel	Cancer
T-Type calcium channel inhibitor 2 (compound 6g) is a potent T-type calcium channel inhibitor with IC₅₀s of 31.0, 83.1, 69.3 µM for Cav3.1 (α1G), Cav3.2 (α1H), Cav3.3 (α1I) (α1H), respectively. T-Type calcium channel inhibitor 2 shows cytotoxicity for A549, HCT-116 cells with IC₅₀s of 5.0, 6.4 µM, respectively .

Nisoldipine 1 Publications Verification BAY-k 5552	Calcium Channel Reactive Oxygen Species	Cardiovascular Disease
Nisoldipine (BAY-k 5552; Sular) is a highly efficient and specific L-type Cav1.2 channel blocker with an IC50 of 10 nM.

Cav 2.2 blocker 1 1 Publications Verification	Calcium Channel	Neurological Disease
Cav 2.2 blocker 1 (compound 9) is a *N-type calcium channel (Cav* 2.2) blocker for the treatment of pain, with an IC₅₀** of 1 nM .

SAK3	Calcium Channel	Neurological Disease
SAK3 is a potent T-type voltage-gated Ca ²⁺ channels (T-VGCCs) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca ²⁺ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice . SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity .

RQ-00311651	Calcium Channel	Neurological Disease
RQ-00311651 is a T-type calcium channel blocker that specifically targets the *Cav3.2* isoform with a role in neuropathic and visceral pain. RQ-00311651 significantly inhibits T currents in HEK293 cells expressing human Cav3.1 or Cav3.2. RQ-00311651 also inhibited high potassium-induced calcium signaling. RQ-00311651 also inhibits antiallergic properties in rats and mice with neuropathic pain induced by spinal nerve injury or Paclitaxel (HY-B0015). Oral and intraperitoneal injection (10-20 mg/kg) inhibits Cerulein (HY-A0190)-induced acute pancreatitis and cyclophosphamide-induced cystitis in mice .

Cavα2δ-IN-1	Calcium Channel	Others
Cavα2δ-IN-1 shows high selectivity for voltage-gated calcium channels Cavα2δ-1 (K_i 6 nM) versus Cavα2δ-2 (K_i ＞ 10000 nM).

CAV1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CAV1 Human Pre-designed siRNA Set A contains three designed siRNAs for CAV1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CAV2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CAV2 Human Pre-designed siRNA Set A contains three designed siRNAs for CAV2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CAV3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CAV3 Human Pre-designed siRNA Set A contains three designed siRNAs for CAV3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cavα2δ1&NET-IN-1	Calcium Channel Monoamine Transporter	Inflammation/Immunology
Cavα2δ1&NET-IN-1 (Compound 59S) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Ca_vα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-1 inhibits Ca_vα2δ-1 with a K_i of 112 nM. Cavα2δ1&NET-IN-1 inhibits NET with a K_i of 383 nM and IC₅₀ of 67 nM. Cavα2δ1&NET-IN-1 can be used for research of pain .

Cavα2δ1&NET-IN-2	Calcium Channel Monoamine Transporter	Inflammation/Immunology
Cavα2δ1&NET-IN-2 (Compound 45CS) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Ca_vα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-2 inhibits Ca_vα2δ-1 with a K_i of 454 nM. Cavα2δ1&NET-IN-2 inhibits NET with a K_i of 59 nM and IC₅₀ of 7 nM. Cavα2δ1&NET-IN-2 can be used for research of pain .

TROX-1	Calcium Channel	Neurological Disease
TROX-1 is an N-type calcium channel (CaV2.2) inhibitor with an IC₅₀ value of 0.11 μM. TROX-1 can be used in chronic pain research .

5,6-Epoxyeicosatrienoic acid 5,6-EET; (±)5,6-EpETrE	Adrenergic Receptor	Endocrinology
5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC₅₀=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone.

TTA-A2 1 Publications Verification	Calcium Channel	Neurological Disease
TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a₁G) and Cav3.2 (a₁H) channels with IC₅₀ values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy .

Cavα2δ1&NET-IN-3	Calcium Channel	Neurological Disease Endocrinology
Cavα2δ1&NET-IN-3 (example 216) is an inhibitor of the subunit α2δ of voltage-gated calcium channels (VGCC) and noradrenaline transporter (NET). Cavα2δ1&NET-IN-3 has K_is of 100-500 nM for human α2δ-1 subunit of Ca_v2.2 calcium channel and NET, respectively .

Nisoldipine (Standard)	Calcium Channel Reactive Oxygen Species	Cardiovascular Disease
Nisoldipine (Standard) is the analytical standard of Nisoldipine. This product is intended for research and analytical applications. Nisoldipine (BAY-k 5552; Sular) is a highly efficient and specific L-type Cav1.2 channel blocker with an IC50 of 10 nM.

Cav 3.2 inhibitor 1	Calcium Channel	Neurological Disease Inflammation/Immunology
Cav 3.2 inhibitor 1 is a T-type calcium channel inhibitor with little binding affinity to dopamine D2 receptors. Cav 3.2 inhibitor 1 can be used for the research of somatic and visceral pain .

GTx1-15	Sodium Channel Calcium Channel	Neurological Disease
GTx1-15 is an inhibitor cystine knot (ICK) peptide that inhibits the voltage-dependent calcium channel Cav3.1 and the voltage-dependent sodium channels Nav1.3 and Nav1.7 .

L-Ascorbic acid sodium salt Maximum Cited Publications 46 Publications Verification Sodium ascorbate; Sodium L-ascorbate; Vitamin C sodium salt	Calcium Channel Reactive Oxygen Species Apoptosis Endogenous Metabolite	Cancer
L-Ascorbic acid sodium salt (Sodium ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid sodium salt selectively inhibits Ca_v3.2 channels with an IC₅₀ of 6.5 μM. L-Ascorbic acid sodium salt is also a collagen deposition enhancer and an elastogenesis inhibitor .

Kurtoxin	Calcium Channel Sodium Channel	Neurological Disease
Kurtoxin is a selective Cav3 (T-type) voltage-gated Ca ²⁺ channel gating inhibitor with a K_d of 15 nM for Cav3.1 (α1G T-type) Ca ²⁺ channel. Kurtoxin can interact with high affinity with native neuronal high-threshold L-type, N-type, and P-type Ca ²⁺ channels in central and peripheral neurons. Kurtoxin also shows cross-reactivity with voltage-gated Na ⁺ channel .

NNC 55-0396 4 Publications Verification NNC 55-0396 dihydrochloride	Calcium Channel	Cardiovascular Disease Neurological Disease
NNC 55-0396 is a highly selective T-type calcium channel blocker with an IC₅₀ value of 6.8 μM for Cav3.1 T-type channels. NNC 55-0396 can be used for the research of neurological disease research .

SNX-482	Calcium Channel	Neurological Disease
SNX-482, a peptidyl toxin of the spider Hysterocrates gigas, is a potent, high affinity, selective and voltage-dependent R-type Ca_V2.3 channel blocker with an IC₅₀ of 30 nM. SNX-482 has antinociceptive effect .

L-Ascorbic acid sodium salt (Standard)	Calcium Channel Reactive Oxygen Species Apoptosis Endogenous Metabolite	Cancer
L-Ascorbic acid (sodium salt) (Standard) is the analytical standard of L-Ascorbic acid (sodium salt). This product is intended for research and analytical applications. L-Ascorbic acid sodium salt (Sodium ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid sodium salt selectively inhibits Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid sodium salt is also a collagen deposition enhancer and an elastogenesis inhibitor .

Cat. No.	Product Name	Type

HY-B0166GL

L-Ascorbic acid (GMP Like)

L-Ascorbate (GMP Like); Vitamin C (GMP Like)

Fluorescent Dye

L-Ascorbic acid (GMP Like) is the GMP Like class L-Ascorbic acid (HY-B0166). L-Ascorbic acid (L-Ascorbate, Vitamin C), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Ca_v3.2 channels with an IC₅₀ of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .

HY-B0166G

L-Ascorbic acid (GMP) L-Ascorbate (GMP); Vitamin C (GMP)	Fluorescent Dye
L-Ascorbic acid (L-Ascorbate) (GMP) is L-Ascorbic acid (HY-B0166) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Ascorbic acid is an inhibitor of Ca_v 3.2 channels .

Cat. No.	Product Name	Type

HY-B0166GL

L-Ascorbic acid (GMP Like)

L-Ascorbate (GMP Like); Vitamin C (GMP Like)

Biochemical Assay Reagents

HY-B0166G

L-Ascorbic acid (GMP) L-Ascorbate (GMP); Vitamin C (GMP)	Biochemical Assay Reagents
L-Ascorbic acid (L-Ascorbate) (GMP) is L-Ascorbic acid (HY-B0166) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Ascorbic acid is an inhibitor of Ca_v 3.2 channels .

Cat. No.	Product Name	Target	Research Area

HY-P2288A

WL47 TFA 2 Publications Verification	Peptides	Cancer
WL47 TFA, a high-affinity *cavolin-1 (CAV1) ligand* (K_d=23 nM), is a potent disrupter of CAV1 oligomers. WL47 TFA shows selectivity for CAV1 over BSA, casein and HEWL. WL47 TFA is 80% smaller in length than the original T20 (HY-P0052) parent sequence and can be used for the study of caveolin-1 function .

HY-P1074

SNX-482	Calcium Channel	Neurological Disease
SNX-482, a peptidyl toxin of the spider Hysterocrates gigas, is a potent, high affinity, selective and voltage-dependent R-type Ca_V2.3 channel blocker with an IC₅₀ of 30 nM. SNX-482 has antinociceptive effect .

HY-P2288

WL47	Peptides	Cancer
WL47, a high-affinity *cavolin-1 (CAV1) ligand* (K_d=23 nM), is a potent disrupter of *CAV1* oligomers. WL47 shows selectivity for CAV1 over BSA, casein and HEWL. WL47 is 80% smaller in length than the original T20 (HY-P0052) parent sequence and can be used for the study of caveolin-1 function .

HY-P10332

WL 47 dimer	Peptides	Others
WL 47 dimer (ligand 1) is a caveolin-1 (CAV-1) ligand with high affinity, selectivity and oligomer dissociation activity. WL 47 dimer simultaneously occupies two binding sites of *CAV-1, inducing the dissociation of oligomers. WL 47 dimer has 7500-fold improved affinity compared to its T20 parent ligand and an 80% decrease in sequence length. WL 47 dimer can be used to permit targeted study of CAV-1* function .

HY-P5793

GTx1-15	Sodium Channel Calcium Channel	Neurological Disease
GTx1-15 is an inhibitor cystine knot (ICK) peptide that inhibits the voltage-dependent calcium channel Cav3.1 and the voltage-dependent sodium channels Nav1.3 and Nav1.7 .

HY-P5869

Kurtoxin	Calcium Channel Sodium Channel	Neurological Disease
Kurtoxin is a selective Cav3 (T-type) voltage-gated Ca ²⁺ channel gating inhibitor with a K_d of 15 nM for Cav3.1 (α1G T-type) Ca ²⁺ channel. Kurtoxin can interact with high affinity with native neuronal high-threshold L-type, N-type, and P-type Ca ²⁺ channels in central and peripheral neurons. Kurtoxin also shows cross-reactivity with voltage-gated Na ⁺ channel .

HY-P5874

Myr-TAT-CBD3	Calcium Channel	Inflammation/Immunology
Myr-TAT-CBD3 is *CRMP2-CaV2.2* interaction inhibitor. Myr-tat-CBD3 can significantly attenuate carrageenan-induced thermal hypersensitivity and reverse thermal hypersensitivity induced in a rat model of postoperative pain. Myr-TAT-CBD3 can be used to study inflammation and postoperative pain .

HY-P1073

ProTx-I	Calcium Channel Sodium Channel Potassium Channel	Cancer
ProTx-I, a venom toxin of the tarantula Thrixopelma pruriens, is a potent, selective Ca_V3.1 channel blocker with IC₅₀ values of 0.2 μM and 31.8 μM for hCa_V3.1 and hCa_V3.2 respectively. ProTx-I is also a potent blocker for voltage-gated Na ⁺ channels and inhibits K_V 2.1 channels .

HY-P5813

Cd1a β-TRTX-cd1a; β-Theraphotoxin-cd1a	Peptides	Neurological Disease
Cd1a is a β-toxin derived from the African spider Ceratogyrus darlingi. Cd1a can regulate calcium ion channels. Cd1a inhibits human calcium ion channels (Ca_v2.2)(IC₅₀2.6 μM) and mouse sodium ion channels (Na_v1.7). Cd1a can be used in the development of peripheral pain treatment drugs .

HY-P5796

FS-2	Calcium Channel	Neurological Disease
FS-2 is a potent and specific *L-type Ca_V* channel** inhibitor. FS-2 inhibits high K ⁺ or glucose induced L-type Ca ²⁺ influx in RIN beta cells .

HY-P1080

ω-Agatoxin IVA	Calcium Channel	Neurological Disease
ω-Agatoxin IVA is a potent, selective *P/Q type Ca ²⁺ (Cav2.1) channel* blocker with IC₅₀s of 2 nM and 90 nM for P-type and Q-type Ca ²⁺ channels, respectively. ω-Agatoxin IVA (IC₅₀, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA has no effect on L-type or N-type calcium channels .

HY-P1080A

ω-Agatoxin IVA TFA	Calcium Channel	Neurological Disease
ω-Agatoxin IVA TFA is a potent, selective *P/Q type Ca ²⁺ (Cav2.1) channel* blocker with IC₅₀s of 2 nM and 90 nM for P-type and Q-type Ca ²⁺ channels, respectively. ω-Agatoxin IVA TFA (IC₅₀, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA TFA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA TFA has no effect on L-type or N-type calcium channels .

HY-P1441A

Mambalgin 1 TFA	Sodium Channel	Neurological Disease
Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC₅₀ values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.

Cat. No.	Product Name	Chemical Structure

HY-B0166S3

L-Ascorbic acid-13C-2
L-Ascorbic acid- ¹³C-2 is the ¹³C labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen

HY-103309S

ML218-d9

ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier[1].

HY-17402S

Nisoldipine-d6
Nisoldipine-d₆ is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552; Sular) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with an IC50 of 10 nM.

HY-17402S3

Nisoldipine-d3
Nisoldipine-d₃ is deuterated labeled Nisoldipine (HY-17402). Nisoldipine (BAY-k 5552; Sular) is a highly efficient and specific L-type Cav1.2 channel blocker with an IC50 of 10 nM.

HY-B0166S6

L-Ascorbic acid-d2
L-Ascorbic acid-d₂ is the deuterium labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a colla

HY-17402S1

Nisoldipine-d4
Nisoldipine-d₄ (BAY-k 5552-d4) is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC50 of 10 nM[1][2].

HY-17402S2

Nisoldipine-d7
Nisoldipine-d₇ (BAY-k 5552-d7) is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC50 of 10 nM[1][2].

HY-B0166S2

L-Ascorbic acid-13C-1
L-Ascorbic acid- ¹³C-1 is the ¹³C labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen

HY-B0166S4

L-Ascorbic acid-13C-3
L-Ascorbic acid- ¹³C-3 is the ¹³C labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen

HY-B0166S5

L-Ascorbic acid-13C-4
L-Ascorbic acid- ¹³C-4 is the ¹³C labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collag

HY-B0166S

L-Ascorbic acid-13C6

L-Ascorbic acid- ¹³C₆ is the ¹³C-labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor[1][2][3]. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells[4].

HY-B0166S1

L-Ascorbic acid-13C

L-Ascorbic acid- ¹³C is the ¹³C-labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor[1][2][3]. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells[4].

HY-B1858S

Isoprothiolane-d4
Isoprothiolane-d₄ is the deuterium labeled Isoprothiolane. Isoprothiolane is a systemic fungicide. Isoprothiolane is a rice blast controlling agent against the fungal disease of rice planty Pyvioutavia oryzae Cav[1][2].

HY-112499S

Menaquinone-7-d7

Menaquinone-7-d₇ is the deuterium labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors[1]. Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins [2]. Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS)[3].

HY-112499S1

Menaquinone-7-13C6

Menaquinone-7- ¹³C₆ is the ¹³C-labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors[1]. Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins [2]. Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS)[3].

HY-B0166S8

L-Ascorbic acid-13C6-1

L-Ascorbic acid- ¹³C₆-1 (L-Ascorbate-1; Vitamin C- ¹³C₆-1) is a ¹³C labeled L-Ascorbic acid (HY-B0166) . L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Ca_v3.2 channels with an IC₅₀ of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .

Cat. No.	Product Name		Classification

HY-RS01986

CAV1 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
CAV1 Human Pre-designed siRNA Set A contains three designed siRNAs for CAV1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS01987

CAV2 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
CAV2 Human Pre-designed siRNA Set A contains three designed siRNAs for CAV2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS01988

CAV3 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
CAV3 Human Pre-designed siRNA Set A contains three designed siRNAs for CAV3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CAVS

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products